

GLAXOSMITHKLINE PLC

Form 6-K

April 12, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 12 April 2016 that the following Directors and Persons Discharging Managerial Responsibilities ('PDMR') acquired GSK Ordinary Shares ('Shares') on 11 April 2016, at a price of 1472.57 pence per Ordinary Share, through GSK's ShareReward Plan (the 'Plan'):

Director/PDMR	Number of Shares under the personal contribution element of the Plan	Number of Shares under the matching element of the Plan (GSK contribution)
Sir Andrew Witty	9	9
Mr R G Connor	9	9
Mr S Dingemans	9	9
Mr N Hirons	9	9
Mr S A Hussain	9	9
Mr D S Redfern	9	9
Ms C Thomas	9	9
Mr P C Thomson	9	9
Dr P J T Vallance	8	8
Ms E Walmsley	9	9
Mrs V A Whyte	9	9

V A Whyte  
Company Secretary

12 April 2016

SIGNATURES

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 12, 2016

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc